These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 30852762)

  • 1. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.
    Xiao H; Bid HK; Chen X; Wu X; Wei J; Bian Y; Zhao C; Li H; Li C; Lin J
    PLoS One; 2017; 12(7):e0180297. PubMed ID: 28672024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
    Fu S; Chen X; Lo HW; Lin J
    Cancer Lett; 2019 Apr; 448():11-19. PubMed ID: 30707920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
    Wu X; Cao Y; Xiao H; Li C; Lin J
    Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
    Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
    Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy.
    Wei J; Ma L; Lai YH; Zhang R; Li H; Li C; Lin J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):63. PubMed ID: 30736824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
    Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
    Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bazedoxifene, a GP130 Inhibitor, Modulates EMT Signaling and Exhibits Antitumor Effects in HPV-Positive Cervical Cancer.
    Kim L; Park SA; Park H; Kim H; Heo TH
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
    Park SA; Kim LK; Park HM; Kim HJ; Heo TH
    Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of bazedoxifene analogues targeting glycoprotein 130.
    Song D; Yu W; Ren Y; Zhu J; Wan C; Cai G; Guo J; Zhang W; Kong L
    Eur J Med Chem; 2020 Aug; 199():112375. PubMed ID: 32388278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells.
    Fu S; Lin J
    Anticancer Res; 2018 Nov; 38(11):6271-6279. PubMed ID: 30396947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.
    Chen X; Tian J; Su GH; Lin J
    Curr Cancer Drug Targets; 2019; 19(5):417-427. PubMed ID: 29714141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
    Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
    Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing the selective estrogen receptor modulator
    Thilakasiri P; Huynh J; Poh AR; Tan CW; Nero TL; Tran K; Parslow AC; Afshar-Sterle S; Baloyan D; Hannan NJ; Buchert M; Scott AM; Griffin MD; Hollande F; Parker MW; Putoczki TL; Ernst M; Chand AL
    EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30885958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
    Li H; Xiao H; Lin L; Jou D; Kumari V; Lin J; Li C
    J Med Chem; 2014 Feb; 57(3):632-41. PubMed ID: 24456369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.